Table 1 Patient characteristics
Characteristics (n = 102) | N | % | Characteristics | N | % |
|---|---|---|---|---|---|
Patient characteristics | AST | ||||
Sex | ≤ 30 U/L | 83 | 81.4 | ||
Male | 83 | 81.4 | > 30 U/L | 19 | 18.6 |
Age | Alb | ||||
Median (range), years | 67.5 (28–83) | < 3.5 g/dL | 33 | 32.4 | |
ECOG-PS | ≥ 3.5 g/dL | 69 | 67.6 | ||
0 | 64 | 62.7 | CRP | ||
1 | 23 | 22.6 | ≤ 0.5 g/dL | 44 | 43.1 |
≥ 2 | 15 | 14.7 | > 0.5 g/dL | 58 | 56.9 |
Histology type | ALP | ||||
Clear cell | 76 | 96.2 | ≤ 322 U/L | 61 | 61.6 |
Non-clear cell | 3 | 3.8 | > 322 U/L | 38 | 38.4 |
Prior nephrectomy | 75 | 73.5 | mGPS | ||
Metastatic sites | 0 | 42 | 41.2 | ||
Lung | 69 | 67.6 | 1 | 28 | 27.5 |
Bone | 25 | 24.5 | 2 | 32 | 31.3 |
Lymph node | 30 | 29.4 | NLR | ||
Liver | 15 | 14.7 | ≤ 3.5 | 64 | 64 |
Other | 23 | 22.5 | > 3.5 | 36 | 36 |
Number of metastatic sites | PLT | ||||
0 | 3 | 2.9 | ≤ 310 × 109/L | 71 | 69.6 |
1 | 45 | 44.2 | > 310 × 109/L | 31 | 30.4 |
≥ 2 | 54 | 52.9 | COP-NLR | ||
MSKCC risk group | 0 | 49 | 49 | ||
Favorable | 13 | 12.8 | 1 | 36 | 36 |
intermediate | 70 | 68.6 | 2 | 15 | 15 |
poor | 19 | 18.6 | Laboratory data within the first 6 weeks of sunitinib | ||
Treatment characteristics | Hb | ||||
Prior immunotherapy | 21 | 20.6 | < 12 g/dL | 55 | 53.9 |
Prior targeted therapy | 13 | 12.7 | ≥ 12 g/dL | 47 | 46.1 |
Treatment | Ca | ||||
1st line | 75 | 73.5 | < 10 g/dL | 80 | 83.3 |
2st line | 18 | 17.7 | ≥ 10 g/dL | 16 | 16.7 |
3st line | 9 | 8.8 | LDH | ||
Initial dose | ≤ 333 U/L | 76 | 76 | ||
50 mg | 47 | 46 | > 333 U/L | 24 | 24 |
37.5 mg | 42 | 41.2 | AST | ||
25 mg | 12 | 11.8 | ≤ 30 U/L | 62 | 60.8 |
12.5 mg | 1 | 1 | > 30 U/L | 40 | 39.2 |
Treatment schedule | CRP | ||||
4-week on / 2-week off | 35 | 34.3 | ≤ 0.5 g/dL | 26 | 25.7 |
2-week on / 1-week off | 64 | 62.7 | > 0.5 g/dL | 75 | 74.3 |
Other | 3 | 3 | mGPS | ||
RDI during the first 6 weeks of sunitinib | 0 | 24 | 24.2 | ||
Median (range), % | 62.5 (17.9–100) | 1 | 26 | 26.3 | |
Duration of therapy | 2 | 49 | 49.5 | ||
Median (range), days | 140 (5–2012) | NLR | |||
Laboratory data at start of sunitinib | ≤ 3.5 | 71 | 74 | ||
Hb | > 3.5 | 25 | 26 | ||
< 12 g/dL | 55 | 53.9 | PLT | ||
≥ 12 g/dL | 47 | 46.1 | ≤ 310×109/L | 97 | 95.1 |
Ca | > 310×109/L | 5 | 4.9 | ||
< 10 g/dL | 82 | 83.7 | COP-NLR | ||
≥ 10 g/dL | 16 | 16.3 | 0 | 71 | 74 |
LDH | 1 | 22 | 22.9 | ||
≤ 333 U/L | 91 | 90.1 | 2 | 3 | 3.1 |
> 333 U/L | 10 | 9.9 | |||